Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo

The oncolytic herpes simplex virus (HSV) G47Δ can selectively eliminate glioblastoma cells via viral replication and temozolomide (TMZ) has been clinically used to treat glioblastoma. However, the combined effect of G47Δ and TMZ on cancer cells, particularly on breast cancer cells, remains largely u...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Jingjing, Jiang, Hua, Cheng, Lin, Ma, Binlin, Liu, Renbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751368/
https://www.ncbi.nlm.nih.gov/pubmed/33376532
http://dx.doi.org/10.3892/ol.2020.12360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751368/
https://www.ncbi.nlm.nih.gov/pubmed/33376532
http://dx.doi.org/10.3892/ol.2020.12360

Ejemplares similares